Table 3.
Examples of clinical trials with results involved in neurological diseases, cancer, cardiovascular, and Orthopedics, from http://clinicaltrials.gov/.
| Conditions | Registration | Sample size | Study design | Treatment | Outcomes | Ref. |
|---|---|---|---|---|---|---|
| Alzheimer’s Disease | NCT01297218/NCT01696591 | Nine cases divided into: three cases treated with low dose and six treated with high dose | Phase 1 | hUCB-MSCs | Injecting hUCB-MSCs into the hippocampus and precuneus using stereotactic was safe, feasible, and well tolerated | 278 |
| NCT02054208/ NCT03172117 | Nine patients were divided into three who received a low dose, and six received a high dose of hUCB-MSCs | Phase 1/ 2 | hUCB-MSCs | It was conceivable, comparatively, and adequately safe to administer hUCB-MSCs three times into the lateral ventricle using an Ommaya reservoir | 279 | |
| Parkinson’s disease | NCT03550183 | — | Phase 1 | (UCMSC) | Ensuring safety and effectiveness study of Parkinson’s disease patients via transplant of hUCB-MSCs | 280 |
| NCT03309514 | — | Phase 1/2 | Autologous Hope Biosciences-ADMSCs | Used to investigate the safety and effectiveness of transplanting adult neural stem cells derived from the central nervous system in specific individuals with Parkinson’s disease | ||
| Spinal cord injury | — | Sixteen patients were classified into a group injected with a low dose and another group with a high dose | Phase 3 | Autologous MSCs | Applying a single MSC to the intramedullary and intradural region is considered safe, but its therapeutic impact is significantly weaker when compared to the injection of several MSCs | 281 |
| — | Twelve individuals with chronic and complete paraplegia | Phase 1/2 | Autologous-BMSCs | Administration of personalized MSC therapy is a safe approach that results in evident enhancements in clinical parameters and the overall well-being of individuals suffering from total and long-standing paraplegia | 282 | |
| Cardiovascular | NCT01739777 | Thirty cases divided into 15 individuals who received an injection and another 15-control group | Phase 1/2 | UCMSC | safety and effectiveness of using uCMSC in individuals diagnosed with heart failure | 283 |
| — | Forty patients | Phase 2 | Autologous CD133+ stem cells | Providing evidence that isolating and delivering autologous CD133+ cells on the same day as coronary artery bypass grafting is both safe and achievable | 284 | |
| Cancer | NCT01579812 | Thirty-eight patients were divided into 1 at the IIC stage, 25 at III stage, and 12 at the IV stage | Phase 2 | Carcinoma-associated mesenchymal stem cells (CA-MSCs) | Antitumor effect on ovarian cancer | 285 |
| NCT03087409 | Eight hundred eighty-five cases | Phase 3 | High-dose chemotherapy with hematopoietic stem cell | Cumulative survival and safety to heal breast cancer | 286 | |
| Orthopedics and musculoskeletal disorders | ACTRN12614000814673 | Thirty participants were classified into three groups: two treatment groups were administered intra-articular ADMSC therapy, either with a single injection or two injections, and the third group was control | NA | Autologous-ADMSC | Effective and safe therapy for knee osteoarthritis | 127 |
| — | Seven participants, four were received a low dose, and another three participants received a high dose | Phase 1/2 | hUCB-MSCs | hUCB-MSCs seemed to be Safe and effective | 287 |